Baur, B; Oroszlan, M; Hess, O; Carrel, T; Mohacsi, P (2011). Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis. Transplantation proceedings, 43(5), pp. 1853-61. New York, N.Y.: Elsevier 10.1016/j.transproceed.2011.01.174
Full text not available from this repository. (Request a copy)Since its introduction as an immunosuppressant in the late 1990s, sirolimus (SRL) has been used to prevent rejections after heart transplantation (HTx) in the United States. An analogue, everolimus (ERL) has been mainly used in Europe. We performed a retrospective longitudinal single-center study to evaluate efficacy and side effects of SRL and ERL.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology 04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Heart Surgery |
UniBE Contributor: |
Hess, Otto, Carrel, Thierry, Mohacsi, Paul |
ISSN: |
0041-1345 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:20 |
Last Modified: |
27 Feb 2024 14:29 |
Publisher DOI: |
10.1016/j.transproceed.2011.01.174 |
PubMed ID: |
21693289 |
Web of Science ID: |
000292279800086 |
URI: |
https://boris.unibe.ch/id/eprint/6606 (FactScience: 211602) |
Actions (login required)
 |
Edit item |